| Dr Emese Kalnoki-kis, MD | |
|
185 Queen City Ave, Manchester, NH 03101-7121 | |
| (603) 314-6450 | |
| (603) 314-6459 |
| Full Name | Dr Emese Kalnoki-kis |
|---|---|
| Gender | Female |
| Speciality | Plastic And Reconstructive Surgery |
| Experience | 22 Years |
| Location | 185 Queen City Ave, Manchester, New Hampshire |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336345362 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208200000X | Plastic Surgery | 287964-1 (New York) | Secondary |
| 208200000X | Plastic Surgery | T1033 (New Hampshire) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Elliot Hospital | Manchester, NH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Elliot Professional Services | 6103727920 | 304 |
News Archive
The Haitian health ministry on Sunday said there had been 2,535 cholera deaths since the outbreak hit in mid-October, "dashing hopes the fatality rate might be beginning to taper off," Agence France-Presse reports.
AstraZeneca today announced the start of a Phase III study (FALCON), a global clinical trial which will involve 450 postmenopausal patients with hormone receptor-positive locally advanced or metastatic breast cancer who have not previously been treated with any hormonal therapy. The Phase III study is designed to evaluate the efficacy and tolerability of fulvestrant 500 mg compared to anastrozole 1 mg in this patient population.
A new way to cleanly separate out cancer cells from a blood sample enables comprehensive genetic profiling of the cancer cells, which could help doctors target tumors and monitor treatments more effectively.
Nabi Biopharmaceuticals announced today that the closing requirements set forth in the exclusive option and license agreement for NicVAX® (Nicotine Conjugate Vaccine), dated November 13, 2009 with GlaxoSmithKlineBiologicals S.A. have been met and the companies have closed the agreement.
› Verified 1 days ago
| Entity Name | Elliot Professional Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285627935 PECOS PAC ID: 6103727920 Enrollment ID: O20040115000634 |
News Archive
The Haitian health ministry on Sunday said there had been 2,535 cholera deaths since the outbreak hit in mid-October, "dashing hopes the fatality rate might be beginning to taper off," Agence France-Presse reports.
AstraZeneca today announced the start of a Phase III study (FALCON), a global clinical trial which will involve 450 postmenopausal patients with hormone receptor-positive locally advanced or metastatic breast cancer who have not previously been treated with any hormonal therapy. The Phase III study is designed to evaluate the efficacy and tolerability of fulvestrant 500 mg compared to anastrozole 1 mg in this patient population.
A new way to cleanly separate out cancer cells from a blood sample enables comprehensive genetic profiling of the cancer cells, which could help doctors target tumors and monitor treatments more effectively.
Nabi Biopharmaceuticals announced today that the closing requirements set forth in the exclusive option and license agreement for NicVAX® (Nicotine Conjugate Vaccine), dated November 13, 2009 with GlaxoSmithKlineBiologicals S.A. have been met and the companies have closed the agreement.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Emese Kalnoki-kis, MD 185 Queen City Ave, Manchester, NH 03101-7121 Ph: (603) 146-4503 | Dr Emese Kalnoki-kis, MD 185 Queen City Ave, Manchester, NH 03101-7121 Ph: (603) 314-6450 |
News Archive
The Haitian health ministry on Sunday said there had been 2,535 cholera deaths since the outbreak hit in mid-October, "dashing hopes the fatality rate might be beginning to taper off," Agence France-Presse reports.
AstraZeneca today announced the start of a Phase III study (FALCON), a global clinical trial which will involve 450 postmenopausal patients with hormone receptor-positive locally advanced or metastatic breast cancer who have not previously been treated with any hormonal therapy. The Phase III study is designed to evaluate the efficacy and tolerability of fulvestrant 500 mg compared to anastrozole 1 mg in this patient population.
A new way to cleanly separate out cancer cells from a blood sample enables comprehensive genetic profiling of the cancer cells, which could help doctors target tumors and monitor treatments more effectively.
Nabi Biopharmaceuticals announced today that the closing requirements set forth in the exclusive option and license agreement for NicVAX® (Nicotine Conjugate Vaccine), dated November 13, 2009 with GlaxoSmithKlineBiologicals S.A. have been met and the companies have closed the agreement.
› Verified 1 days ago
Dr. Bruce M. Topol, M.D. Plastic Surgery Medicare: Not Enrolled in Medicare Practice Location: 36 Bay St, Manchester, NH 03104 Phone: 603-622-0900 Fax: 603-622-5955 | |
Robert S Feins, M.D. Plastic Surgery Medicare: Not Enrolled in Medicare Practice Location: 144 Tarrytown Rd, Manchester, NH 03103 Phone: 603-647-4430 Fax: 603-647-4877 | |
Peter Thomas Pacik, M.D. Plastic Surgery Medicare: Not Enrolled in Medicare Practice Location: 57 Bay St, Manchester, NH 03104 Phone: 603-669-0290 Fax: 603-669-4040 |